Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 127,710

Document Document Title
WO/2017/150475A1
[Problem] To develop a brain health food/brain health beverage for preventing/alleviating brain atrophy due to alcohol intake. [Solution] A brain health food or brain health beverage containing, as active ingredients, folic acid, vitamin...  
WO/2017/147720A1
A method of treating a central nervous system disorder in a mammal is provided. The method comprises administering to the mammal a therapeutically effective amount of non-naturally occurring exosomes engineered to comprise nucleic acid e...  
WO/2017/149339A1
The present invention relates to compounds of formula (I), which are blocked in C3 position and cannot metabolize in vivo into pregnenolone derivatives and which do not have significant affinity for steroid hormonal receptors and for all...  
WO/2017/150686A1
The present invention provides a composition that is effective in improving the symptoms of autism spectrum disorder. The composition is characterized in containing, as an active ingredient, at least one type of pyridoxamine compound sel...  
WO/2017/150327A1
The present invention addresses the problem of providing a food material that is added to food to promote in-brain secretion of neurotrophins including BDNF, and that can endow the food with a brain function improvement function and a cr...  
WO/2017/148960A1
The present invention relates to compositions for use in the treatment of neurological disease. In one embodiment, the present invention relates to a peptide analogue of xenin or gastric inhibitory polypeptide for use in the treatment of...  
WO/2017/150566A1
The present invention provides a model animal for establishing an effective treatment for protein aggregate diseases typified by Alzheimer's disease and the like. More specifically, the present invention provides the following. (A) A non...  
WO/2017/149387A1
Disclosed are stable compositions comprising at least one CB2 receptor selective or highly selective agonist and optionally at least one antipsychotic for use in the treatment of mental disorders, methods of preparing such compositions a...  
WO/2017/147285A9
The present invention is directed to a sustained release buprenorphine microsphere (SRBM) formulation capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 7 days to about 6 months.  
WO/2017/147147A1
Provided herein are compositions for treating acute, chronic, or post-operative pain in a subject, said compositions comprising a Nav1.7 selective inhibitor and a biodegradable carrier, wherein the agent is incorporated within the biodeg...  
WO/2017/147285A1
The present invention is directed to a sustained release buprenorphine microsphere (SRBM) formulation capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 7 days to about 6 months.  
WO/2017/147536A1
Compositions and methods disclosed concern an isogenic population of in vitro human embryonic stem cells comprising a disease form of the Huntingtin gene (HTT) at the endogenous HTT gene locus in the genome of the cell; wherein the disea...  
WO/2017/143990A1
The present invention provides a method for preparing a pyrrolopyrimidine compound and application thereof. Specifically, the present invention provides a compound represented by formula I or pharmaceutically-acceptable salts thereof, a ...  
WO/2017/146230A1
The purpose of the present invention is to provide an extract from inflammatory tissue inoculated with vaccinia virus, a test method using a novel method of administration of a formulation containing the extract, and the like. With the p...  
WO/2017/147529A1
The present invention relates to methods of treating neurodegenerative disorders associated with Alzheimer's disease (AD), Parkinson's disease (PD) and synucleinopathies, such as dementia with Lewy bodies, Down Syndrome (DS) and associat...  
WO/2017/143967A1
A poly(butyl cyanoacrylate) nanoparticle with dual modifications, a drug delivery system with the nanoparticle, and a preparation method for the nanoparticle and the system. A surface of the nanoparticle is modified by a first modifying ...  
WO/2017/146104A1
An oral cavity patch that comprises a drug layer, said drug layer containing a drug and an infiltration promoter, and an adhesive layer, said adhesive layer containing a mucosa adhering property-imparting component and being fixed to the...  
WO/2017/144393A1
The invention relates to bromodomain-protein-inhibiting, in particular BET-protein-inhibiting, and preferably BRD4-inhibiting 2-substituted 5-(phenyl)-1,2-dihydro-3H-3-benzazepine-3-carboxamide derivatives of general formula (I), where R...  
WO/2017/144995A1
A compound compound having the structure (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A' and A" are independently O, C=O, C-R...  
WO/2017/143836A1
Provided in the present invention are a substituted heteroaryl compound, a composition containing same, and an application thereof, the present invention disclosing a heteroaryl compound of the formula (I), or a crystalline form, a pharm...  
WO/2017/145166A1
The present invention provides a composition and method for treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis, in a subject. The composition in some...  
WO/2017/147375A1
The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cup...  
WO/2017/147379A1
The present invention provides the use of compounds which selectively block the Nav1.1 subtype of voltage-gated sodium (Nav) channels, whose role in nociception and pain has been unexplored. The present invention demonstrates that Nav1.1...  
WO/2017/145013A1
The present invention is directed to PDE4B inhibitors of Formula I: (I) or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R2, R 3, and R 4are as defined herein. The invention is also directed to pharmaceutical c...  
WO/2017/143397A1
The present invention relates to compounds and their uses. In particular, to compounds that inhibit the interaction between β-arrestin and the intracellular C-terminus of the activated NK1R and their use in the treatment of pain.  
WO/2017/144637A1
The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and in particular as glycosidase inhibitors.  
WO/2017/143451A1
Antibodies to human CD11d, compositions comprising such CD11d antibodies, and methods of using such CD11d antibodies for the treatment of central nervous system trauma including spinal cord injury and traumatic brain injury, as well as s...  
WO/2017/146053A1
Provided are: pharmaceutical composition particles and an orally disintegrating tablet including the same which are capable of achieving both the masking of unpalatable taste and an improvement in elution properties; and a method for pro...  
WO/2017/147414A1
The present disclosure relates in general to therapeutic lysosomal enzyme fusion proteins useful for treating lysosomal storage diseases, liquid formulations comprising such fusion proteins and associated methods useful for treating lyso...  
WO/2017/140684A2
The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction...  
WO/2017/142424A1
Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have, or are at risk for, Alzheimer's disease comprising tetramine copper chelators in combination with an agent effective to reduce one or more...  
WO/2017/142442A1
The invention relates to the field of medicine and to the chemical-pharmaceutical industry, and pertains to agents for use in the case of sleep disorders. A pharmaceutical composition for initiating and maintaining the sleep process and ...  
WO/2017/140212A1
Provided are a use of Zn7MT3 and derivatives thereof in treating Alzheimer's disease and the use of same in preparing drugs against Alzheimer's disease and neurodegenerative diseases. Also provided is a preparation method for Zn7MT3.  
WO/2017/139971A1
The present invention relates to a crystal form N of aripiprazole, a pharmaceutical composition thereof and the use of the new crystal form in the preparation of a medicine for treating central nervous system diseases, especially schizop...  
WO/2017/139845A1
The invention relates to alpha conotoxin (α-conotoxin) peptides and methods for their preparation. Also described are pharmaceutical compositions comprising alpha conotoxin (α-conotoxin) peptides and their use in the treatment or preve...  
WO/2017/143207A1
This document provides methods and materials for generating GABAergic neurons in brains. For example, methods and materials for using nucleic acid encoding a NeuroD1 polypeptide and nucleic acid encoding a Dlx2 polypeptide to trigger gli...  
WO/2017/141968A1
A pharmaceutical composition and a processed food product having a component with an anxiolytic action are provided: an anxiolytic pharmaceutical composition and processed food product which contain the 1,2,3,4-tetrahydrocyclopenta[b]ind...  
WO/2017/140684A3
The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction...  
WO/2017/142091A1
The present invention provides a therapeutic or prophylactic drug for dementia, said drug containing a xanthine oxidase inhibitor such as a compound represented by formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt t...  
WO/2017/141911A1
The present invention relates to (2E)-N-[2-(dimethylamino)ethyl]-2-hexadecenamide, 2-(diethylamino)ethyl (2E)-2-hexadecenoate, or pharmaceutically acceptable salts thereof. In addition to activating signal transmission via the MAP kinase...  
WO/2017/137535A1
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): (I) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3- kinase...  
WO/2017/137767A1
Compositions comprising 4-hydroxy-3-methoxyacetophenone or metabolite thereof and 2-hydroxy-4-methoxyacetophenone or metabolite thereof for use in the treatment of neurodegenerative diseases, for example for the treatment of neurodegener...  
WO/2017/139210A1
In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiadiazine dioxide compounds bearing an ether linker, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable sal...  
WO/2017/138008A3
A method of modulating protein exocytosis is provided. The method comprising contacting a cell with an agent that modulates the ubiquitin pathway in the Golgi, thereby modulating protein secretion.  
WO/2017/139331A1
The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead compositio...  
WO/2017/138008A2
A method of modulating protein exocytosis is provided. The method comprising contacting a cell with an agent that modulates the ubiquitin pathway in the Golgi, thereby modulating protein secretion.  
WO/2017/137469A1
The present invention relates to the field of medicine, specifically the field of treatment and prevention of cardiovascular diseases.  
WO/2017/137600A1
The present invention relates to methods for treating neurodegenerative diseases and disorders with igmesine.  
WO/2017/138838A1
The invention relates to salts and hydrates of arylcycloalkylamine derivatives of general formula (I) and formula (II), where in formula (I), R1 and R2 signify H, a linear or branched alkyl (C1, C4), a linear or branched alkoxy (C1, C4),...  
WO/2017/139603A1
The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-t...  

Matches 551 - 600 out of 127,710